The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study

Background and Aims. Nonalcoholic fatty liver disease is the leading cause of chronic liver disease globally and can progress to cirrhosis, liver failure, and liver cancer. Current AASLD, AGA, and ADA guidelines recommend assessment for liver fibrosis in all patients with NAFLD. Serum biomarkers for...

Full description

Saved in:
Bibliographic Details
Main Authors: Michael P. Curry, Edward Tam, Caitlin Schneider, Noha Abdelgelil, Tarek Hassanien, Nezam H. Afdhal
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:International Journal of Hepatology
Online Access:http://dx.doi.org/10.1155/2024/8877130
Tags: Add Tag
No Tags, Be the first to tag this record!